Ready 8-Ks
3
Latest filing
June 23, 2026, 10:34 AM ET
Top materiality
0.90
Event mix
other_material ×2 · other ×1
Sentiment
1 pos · 1 neg · 1 neu
Recent 8-K filings for CSDX
Highest-materiality recent filing
CS Diagnostics Corp. restates financial statements for 2022-2025 after $499.4M intangible asset error
- Board determined financial statements for FY 2022-2025 cannot be relied upon due to improper recognition of $499.4M intangible asset from Sept 4, 2023 transaction.
- Company engaged Shah Teelani & Associates as new auditor and KBF Advisory as technical accounting advisor to assist with restatement and re-audit.
-
Board determined financial statements for FY 2022-2025 cannot be relied upon due to improper recognition of $499.4M intangible asset from Sept 4, 2023 transaction.
-
Conversion of all Series B Preferred Stock held by affiliates CS Interpharm and CS Diagnostics Pharma into 112,652,000 common shares.
-
CS Diagnostics files 8-K describing business and CS Protect Hydrogel product
Filing provides general overview of CS Diagnostics Corp. as a medical distribution company.
Materiality & sentiment trend
Max materiality 0.90 · Median 0.55 · Most common event other_material